Epitalon
Also known as Epithalon, Epithalone, AEDG
A synthetic tetrapeptide studied for telomerase activation and aging, with uncertain long-term cancer risk.
Medically reviewed by Dr. Jonathan Snipes, MD
Reviewed for clinical accuracy · Last reviewed July 22, 2026 · Review policy
Quick answer
Epitalon (epithalon) is a synthetic four-amino-acid peptide studied, mostly in Russian research, for telomerase activation and aging. It is not FDA-approved, human evidence is limited, and the FDA's July 2026 PCAC review flagged telomerase activation with uncertain long-term cancer risk.
- Type
- Synthetic tetrapeptide (AEDG)
- FDA status
- Not approved; compounding under review
- Human evidence
- Limited, mostly Russian research
- Evidence grade
- D (Preclinical Only)
- Banned in sport
- Not specifically listed
Key takeaways
- →Epitalon is a synthetic version of a pineal-gland peptide, studied primarily by Russian researchers for aging and longevity.
- →Its headline mechanism is telomerase activation, which is also the source of its main safety question.
- →Human evidence is limited and largely from a single research lineage; it is not FDA-approved.
- →The FDA's July 2026 PCAC briefing flagged telomerase activation with uncertain long-term carcinogenic potential.
Epitalon is a synthetic tetrapeptide modeled on a substance from the pineal gland, studied mostly by a single Russian research lineage for its effects on aging. It is one of the more speculative longevity peptides: the central claim, telomerase activation, is genuinely interesting, but it is also exactly what raises the safety question, and the supporting human evidence is thin.
How Epitalon works
Epitalon is proposed to activate telomerase, the enzyme that maintains the protective caps on chromosomes, which in theory could slow certain aspects of cellular aging. The same activity is double-edged: telomerase is also active in many cancers, which is why activating it raises questions rather than settling them. The mechanism comes largely from preclinical and limited human work and is not confirmed by large independent trials.
What the evidence shows, by use
Each use is graded on the same A-E scale, based on human-trial quality rather than popularity.
Longevity / anti-aging
DPreclinical OnlyStudied mostly in Russian research with limited human data; no large independent trial establishes an anti-aging benefit.
Sleep and general wellness
EAnecdotalUsed for these purposes based on user reports; controlled human evidence is essentially absent.
Dosing
There is no FDA-approved Epitalon product and no validated human dose. Circulating protocols come from community practice and older research, not modern trials. Because supply is largely unregulated research-grade material, any use should be through a licensed clinician rather than research-chemical vendors, and the telomerase question warrants particular caution.
Side effects
- •Injection-site reactions · Reported
- •Drowsiness · Reported
- •Theoretical cancer-risk concern · Reported
Legal & regulatory status
Epitalon is not FDA-approved. Its compounding pathway was under FDA review at the July 2026 PCAC meeting, which flagged telomerase activation with uncertain carcinogenic potential.
Is Epitalonlegal? Full regulatory status →Where to get it: TeleRanked independently ranks the telehealth providers that offer clinician-prescribed peptides. See our Peptide Therapy rankings. We rank providers, we do not sell compounds, and rankings are never for sale.
Frequently asked questions
Does Epitalon reverse aging?+
There is no strong human evidence that it does. The anti-aging claims rest largely on a single research lineage and preclinical work, not large independent trials.
Is Epitalon safe?+
Its long-term safety is uncertain. Because it is proposed to activate telomerase, which is also active in many cancers, the FDA flagged an unresolved carcinogenicity question in its July 2026 review.
How we grade evidence
Grade D: Preclinical Only. Evidence is largely limited to animal or laboratory studies; human data is minimal or absent. Our A-E scale reflects the strength of human evidence, not how popular a compound is.
Sources
- 1.July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee · U.S. Food & Drug Administration
- 2.Compounding and the FDA: Questions and Answers · U.S. Food & Drug Administration